Lineage Cell Therapeutics, Inc. Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent
Lineage Cell Therapeutics, Inc. (LCTX) had Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent of $22.10 million as of 2018-12-31, per its 10-K filed 2020-03-12.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments and Receivables, Net
us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent · last filed 2020-03-12
- 2018-12-31: Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent $22.10M.
| Period end | Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent |
|---|---|
| 2018-12-31 | $22.10M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |